The Prognostic Role of Inflammatory Biomarkers in Metastatic Castration Sensitive Prostate Carcinoma

Semiz H. S., Keskinkılıç M., Ellez H. İ., Arslan A. M., Arayıcı M. E., Kısa E.

euroasian journal of medical investigation, vol.7, no.1, pp.50-57, 2022 (Peer-Reviewed Journal)


Objectives: Due to limited data in the literature on the prognostic value of inflammatory markers neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), and derived NLR (dNLR) in metastatic castration-sensitive prostate cancer (mCSPC), we aimed to determine the role of this markers in the prognosis of mCSPC. Methods: In this study, inflammatory marker values in mCSPC (NLR0, PLR0, dNLR0) and mCRPC (NLR1, PLR1, dNLR1) were calculated. Characteristics of the patients and the effects of inflammatory markers on overall survival (OS) and cancer-specific survival (CSS) were evaluated using appropriate statistical methods. Results: The median age of 124 patients was 68.71 years. No significant difference was found OS in mCSPC NLR0, dNLR0 and PLR0 groups (p>0,05). While the median CSS was statistically longer in the NLR0, dNLR0 and PLR0 low groups (Median:45.9 vs 35.7 months for NLR0, 47.0 vs 34.6 months for dNLR and 46.2 vs 33.9 months, p=0.037, p=0.036, p=0.041 respectively). There was no significant difference in terms of OS and CSS in NLR1 and dNLR1 groups (p>0.05). The patients with low PLR1 showed statistical significantly better OS and CSS (p=0.027 for OS and p=0.006 for CSS). Conclusion: Although inflammatory markers have prognostic value in many cancers, mCSPC which have heterogeneous and complex structures, are still controversial, and more studies are needed for their routine use. Keywords: Castration, inflammation, prostate cancer, prognosis